期刊
EXPERT OPINION ON INVESTIGATIONAL DRUGS
卷 13, 期 9, 页码 1159-1169出版社
ASHLEY PUBLICATIONS LTD
DOI: 10.1517/13543784.13.9.1159
关键词
bactericidal; complicated skin and skin-structure infections; daptomycin; Gram-positive infections; lipopeptide; methicillin-resistant Staphylococcus aureus
The increasing incidence of serious infections caused by anti biotic-resistant Gram-positive bacteria has led to the development of new spectrum-specific agents. One such agent is Cubicin(TM) (daptomycin for injection), the first member of a new class of antibacterials called cyclic lipopeptides. Daptomycin has rapid, concentration-dependent bactericidal activity against most clinically significant Gram-positive pathogens, including vancomycin-resistant enterococci, methicillin-resistant Staphyiococcus aureus, and vancomycin-intermediate and -resistant S. aureus. This cyclic lipopeptide has a unique mechanism of action and exhibits a relatively prolonged concentration-dependent postantibiotic effect in vitro. In September 2003 the US FDA approved daptomycin for the treatment of complicated skin and skin-structure infections. With its once-daily dosing, excellent safety profile and low potential for resistance, daptomycin is a welcome new addition to the armamentarium against Gram-positive infections.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据